← Back to Search

Palliative Care for Pancreatic Cancer

N/A

Waitlist Available

Led By Elizabeth Loggers

Research Sponsored by Fred Hutchinson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Has decisional capacity

Be older than 18 years old

Must not have

Metastatic pancreatic neoplasm

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at time of multidisciplinary tumor board discussion (no more than 14 days after baseline)

Awards & highlights

No Placebo-Only Group

Summary

This trial is looking at how a consultation with palliative care specialists can help improve communication between doctors and patients who are thinking about surgery for pancreatic cancer. Pancreatic surgeries can have serious complications that impact

Who is the study for?

This trial is for patients with pancreatic tumors who are considering surgery. It's designed to see if talking with a palliative care team helps improve communication and decision-making.

What is being tested?

The study tests whether a special meeting (palliative care consultation) can help people understand their surgical options better, by comparing patient experiences with and without this extra support.

What are the potential side effects?

Since the intervention involves discussions rather than medications or procedures, there are no direct medical side effects; however, emotional or psychological distress could occur from discussing serious illness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am capable of making my own health decisions.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My cancer has spread from the pancreas to other parts of my body.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at time of consent

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at time of consent

This trial's timeline: 3 weeks for screening, Varies for treatment, and at time of consent for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percentage of patients randomized to the interventional arm who complete the palliative care consult prior to tumor board (feasibility)

Percentage of recruited patients that consent (acceptability)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm II (Palliative care visit)Experimental Treatment3 Interventions

Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline.

Group II: Arm I (Usual care)Active Control3 Interventions

Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Palliative Care Consultation

2012

N/A

~370

0 / 2Eligibility criteria met